As of Feb 17
| +1.26 / +2.68%|
The 15 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 53.00, with a high estimate of 118.00 and a low estimate of 39.00. The median estimate represents a +9.78% increase from the last price of 48.28.
The current consensus among 16 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.